SNYR Synergy CHC Corp.: Enterprise Value to EBITDA Ratio
Synergy CHC Corp (SNYR) relies on a broad portfolio of trademarks and established retail relationships, which hinders the expansion of new players under strict FDA oversight. The stock price history demonstrates an EV/EBITDA of 0.00. The holding company focuses on reducing operating expenses and preserving the profits of its core assets. Simultaneously, Synergy CHC Corp (SNYR) effectively scales niche beauty brands through modern digital promotion tools.
Comprehensive metric breakdowns and analytics for synergychc.com (SNYR)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
SNYR - Company Net Income|Expected Profit Synergy CHC Corp|SNYR - Company Value to Net Income|Forward P/E Multiple Synergy CHC|SNYR - Price to Net Income Growth Ratio|Enterprise Value to EBITDA Ratio Synergy CHC Corp.|SNYR - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Synergy CHC|SNYR - Earnings per share for the trailing year|Quarterly EPS earnings growth synergychc.com|SNYR - Net earnings per share growth this year
Comprehensive company analysis:Synergy CHC Corporation (SNYR)
Investors must determine whether the current share price of Synergy CHC Corp (SNYR) results from undervaluation or signals a systemic crisis. Analyzing the historical EV/EBITDA multiple allows for a comparison of the total enterprise value, accounting for debt and taxes, against its operating profit, which is critical for assessing the resilience of a diversified portfolio of hygiene and supplement brands amid fierce retail competition.
Competitor analysis
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANI Pharmaceuticals, Inc. ANIP|Total Company Value to Operating Income Before Depreciation Ratio MannKind Corp (MNKD)|AMPH: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Pacira Corp|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TBPH|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA scPharma SCPH|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tectonic Therapeutic, Inc. (TECX)|TNXP (Tonix Pharmaceuticals Holding) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Enterprise Value to EBITDA Multiple Eupraxia Pharmaceuticals, Inc.|BHST: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Invizyne Technologies|ORMP (oramed.com) - Enterprise Value to EBITDA Ratio|Entera Bio - Business Value to Operating Income Before Depreciation|HYFT (MindWalk Holdings) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio abvcpharma.com (ABVC)|EV/EBITDA Multiple CPIX|QNTM (Quantum BioPharma Ltd.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FGEN (FibroGen Corp)|TELO - Enterprise Value to EBITDA Ratio|RANI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio Corporation)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pheton Holdings Limited|Company Value to EBITDA Aptorum APM|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO (impactbiomedinc.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TNF Pharmaceuticals, Inc. TNFA|YCBD (cbdMD Inc.) - Company Value to Operating Income Before Depreciation Ratio|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Altamira Therapeutics CYTO|Lipella Pharmaceuticals (LIPO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OPTN|Enterprise Value to EBITDA Ratio PIRS|Company Value to EBITDA Procaps Group PROC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI (Qilian International Corp) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP (tffpharma.com) - Company Value to Operating Income Before Depreciation Ratio
